Quick Answer
Summit Therapeutics Inc. reported Cash and Equivalents of $225.27 million for fiscal year 2025.
Summit Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $225.27M | +114.8% |
| 2024 | $104.86M | +46.8% |
| 2023 | $71.42M | -79.5% |
| 2022 | $348.61M | +385.6% |
| 2021 | $71.79M | +8.1% |
| 2020 | $66.42M | +4.0% |
| 2019 | $63.84M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $238.55M | +154.4% | -19.9% |
| June 30, 2025 | $297.87M | +947.6% | +40.8% |
| March 31, 2025 | $211.53M | +245.1% | +101.7% |
| December 31, 2024 | $104.86M | +46.8% | +11.8% |
| September 30, 2024 | $93.78M | +294.1% | +229.8% |
| June 30, 2024 | $28.43M | -32.5% | -53.6% |
| March 31, 2024 | $61.29M | -13.6% | -14.2% |
| December 31, 2023 | $71.42M | -79.5% | +200.2% |
- Summit Therapeutics Inc. showed an increase of +114.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Summit Therapeutics Inc.’s cash and equivalents has grown by 252.8% (from $63.84 million to $225.27 million).
- The most recent figure is from Summit Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: